AMA releases CPT codes for pediatric COVID-19 vaccine

The AMA on October 6 issued new Current Procedural Terminology (CPT^®) codes for pediatric doses of Pfizer’s COVID-19 vaccine.

The new codes are as follows:

• 91307: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
• 0071A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
• 0072A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose

The new CPT codes will become effective if the FDA issues approval or emergency use authorization for Pfizer’s two-dose COVID-19 vaccine in children ages five to 11. Revenue integrity professionals should ensure the codes are ready to be deployed in chargemasters if approval or emergency use authorization is granted.

Editor’s note: Find additional NAHRI coverage of COVID-19 vaccines here, and access more NAHRI coverage of charging, coding, billing, and documentation of COVID-19 here.